DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20181005

Analgesic activity of allopurinol and febuxostat in experimental animals

Yajnesh P. Sahu, Sachchidanand Pandey, Sabita Mohapatra

Abstract


Background: Currently, two classes of analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics are used to manage pain in different clinical situations. Chronic uses of these drugs have various adverse effects like gastric ulceration/bleeding, analgesic nephropathy and respiratory depression, physical dependence, addiction, respectively. Xanthine oxidase inhibitors, used for chronic gout, might have a role in alleviation of pain, as per literature survey. Hence, the present study was carried out to evaluate the potential analgesic activity of allopurinol and febuxostat in different experimental models.

Methods: The analgesic activity of allopurinol and febuxostat was assessed by employing two different experimental pain models-tail flick latency model in rats for central analgesia and acetic acid induced writhing model in mice for peripheral analgesia and was compared with tramadol and aspirin.

Results: Allopurinol and febuxostat produced significant central and peripheral analgesic effects as is evident from increase in reaction time in tail flick test and inhibition in number of writhes in acetic acid induced writhing test.

Conclusions: The results of the present study demonstrate marked analgesic effect of allopurinol and febuxostat.


Keywords


Acetic acid induced writhing, Tail flick latency, Xanthine oxidase inhibitor

Full Text:

PDF

References


Rathmell JP, Fields HL. Pain: Pathophysiology and Management, Harrison's Principals of Internal Medicine. 18th ed, Vol. 1. New Delhi: McGrew Hill Publication; 2012:93101.

Schumacher HR, Chen LX. Gout and other crystal associated arthropathies. In: Fauci AS, Jameson JL, Hauser SL, Kasper DL, Longo DL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 18th ed. New Delhi: McGrawHill; 2012:283742.

Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. Goodman and Gilman's the pharmacological basis of therapeutics. 2011;12:959-1004.

Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacological reviews. 2006;58(1):87-114.

McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969;244(22):6049-55.

Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: release and regulation of pain. Progress Neurobiol. 2003;69(5):313-40.

Inkster ME, Cotter MA, Cameron NE. Treatment with xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. Euro J Pharmacol. 2007;561:63-71.

Schmidt AP, Bohmer AE, Antunes C, Schallenberger C, Porincula LO, Elisabetsky E. Antinociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of adenosine A1 receptors. Br J Pharmacol. 2008;156:161-70.

Vogel H. Drug Discovery and Evaluation of Pharmacological Assay. 2nd ed. Berlin: Springer. 2002:3912.

Gilman AG. Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. 1998.

Institute of Laboratory Animal Resources (US). Committee on Care, Use of Laboratory Animals, Norman Grossblatt. Guide for the Care and Use of Laboratory Animals. National Academies; 1978.

Pise HN, Padwal SL, Motghare VM, Deshmukh VS, Jaykare SC, Jadhav SS. Investigation of analgesic activity of xanthine oxidase inhibitor allopurinol: an experimental study. Inter J Pharm Pharmaceu Sci. 2015;7(3).

Schmidt AP, Böhmer AE, Antunes C, Schallenberger C, Porciúncula LO, Elisabetsky E, et al. Analgesic properties of xanthine oxidase inhibitor allopurinol in mice: role of A1adenosine receptor. Br J Pharmacol. 2009;156(1):163-72.

Shankpal PD, Hotwani JH, Chitnis KA, Tadke DS, Kokani VR. Evaluation of analgesic activity of allopurinol and febuxostat in experimental analgesic models in mice. Ind J Pain. 2015;29(2):106.